Methotrexate (MTX) concentration in tumors following low-dose MTX

Naomi J. Winick, Barton A. Kamen, Anita Streckfuss, Johnny Craig, Fred McGuirt, Robert L. Capizzi, Frederick Sklar, Dale Coln

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Methotrexate (MTX) is a folate analog competitive with reduced folates for cellular transport and metabolism. Since the normal plasma folate concentration is only 10-8M, we tested the possibility that there may be a saturable uptake of MTX by proliferating tumor tissue at plasma MTX concentrations of only 10-7 to 10-6M. Patients with advanced malignancies, refractory to accepted therapy, were given low-dose oral MTX (30-60 mg/m2 total dose in four to eight divided doses). Tumor tissue was biopsied 18-24 h after the last oral dose of MTX. The concentrations of MTX and its polyglutamated derivatives were measured in these samples. Forty-eight percent of the drug in the tumor samples was present as a polyglutamated derivative.

Original languageEnglish (US)
Pages (from-to)78-80
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume20
Issue number1
DOIs
StatePublished - Aug 1987

Fingerprint

Methotrexate
Tumors
Folic Acid
Neoplasms
Tissue
Derivatives
Plasmas
Metabolism
Refractory materials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Winick, N. J., Kamen, B. A., Streckfuss, A., Craig, J., McGuirt, F., Capizzi, R. L., ... Coln, D. (1987). Methotrexate (MTX) concentration in tumors following low-dose MTX. Cancer Chemotherapy and Pharmacology, 20(1), 78-80. https://doi.org/10.1007/BF00252965

Methotrexate (MTX) concentration in tumors following low-dose MTX. / Winick, Naomi J.; Kamen, Barton A.; Streckfuss, Anita; Craig, Johnny; McGuirt, Fred; Capizzi, Robert L.; Sklar, Frederick; Coln, Dale.

In: Cancer Chemotherapy and Pharmacology, Vol. 20, No. 1, 08.1987, p. 78-80.

Research output: Contribution to journalArticle

Winick, NJ, Kamen, BA, Streckfuss, A, Craig, J, McGuirt, F, Capizzi, RL, Sklar, F & Coln, D 1987, 'Methotrexate (MTX) concentration in tumors following low-dose MTX', Cancer Chemotherapy and Pharmacology, vol. 20, no. 1, pp. 78-80. https://doi.org/10.1007/BF00252965
Winick, Naomi J. ; Kamen, Barton A. ; Streckfuss, Anita ; Craig, Johnny ; McGuirt, Fred ; Capizzi, Robert L. ; Sklar, Frederick ; Coln, Dale. / Methotrexate (MTX) concentration in tumors following low-dose MTX. In: Cancer Chemotherapy and Pharmacology. 1987 ; Vol. 20, No. 1. pp. 78-80.
@article{30454129326e43e6be4aeff64552bf20,
title = "Methotrexate (MTX) concentration in tumors following low-dose MTX",
abstract = "Methotrexate (MTX) is a folate analog competitive with reduced folates for cellular transport and metabolism. Since the normal plasma folate concentration is only 10-8M, we tested the possibility that there may be a saturable uptake of MTX by proliferating tumor tissue at plasma MTX concentrations of only 10-7 to 10-6M. Patients with advanced malignancies, refractory to accepted therapy, were given low-dose oral MTX (30-60 mg/m2 total dose in four to eight divided doses). Tumor tissue was biopsied 18-24 h after the last oral dose of MTX. The concentrations of MTX and its polyglutamated derivatives were measured in these samples. Forty-eight percent of the drug in the tumor samples was present as a polyglutamated derivative.",
author = "Winick, {Naomi J.} and Kamen, {Barton A.} and Anita Streckfuss and Johnny Craig and Fred McGuirt and Capizzi, {Robert L.} and Frederick Sklar and Dale Coln",
year = "1987",
month = "8",
doi = "10.1007/BF00252965",
language = "English (US)",
volume = "20",
pages = "78--80",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Methotrexate (MTX) concentration in tumors following low-dose MTX

AU - Winick, Naomi J.

AU - Kamen, Barton A.

AU - Streckfuss, Anita

AU - Craig, Johnny

AU - McGuirt, Fred

AU - Capizzi, Robert L.

AU - Sklar, Frederick

AU - Coln, Dale

PY - 1987/8

Y1 - 1987/8

N2 - Methotrexate (MTX) is a folate analog competitive with reduced folates for cellular transport and metabolism. Since the normal plasma folate concentration is only 10-8M, we tested the possibility that there may be a saturable uptake of MTX by proliferating tumor tissue at plasma MTX concentrations of only 10-7 to 10-6M. Patients with advanced malignancies, refractory to accepted therapy, were given low-dose oral MTX (30-60 mg/m2 total dose in four to eight divided doses). Tumor tissue was biopsied 18-24 h after the last oral dose of MTX. The concentrations of MTX and its polyglutamated derivatives were measured in these samples. Forty-eight percent of the drug in the tumor samples was present as a polyglutamated derivative.

AB - Methotrexate (MTX) is a folate analog competitive with reduced folates for cellular transport and metabolism. Since the normal plasma folate concentration is only 10-8M, we tested the possibility that there may be a saturable uptake of MTX by proliferating tumor tissue at plasma MTX concentrations of only 10-7 to 10-6M. Patients with advanced malignancies, refractory to accepted therapy, were given low-dose oral MTX (30-60 mg/m2 total dose in four to eight divided doses). Tumor tissue was biopsied 18-24 h after the last oral dose of MTX. The concentrations of MTX and its polyglutamated derivatives were measured in these samples. Forty-eight percent of the drug in the tumor samples was present as a polyglutamated derivative.

UR - http://www.scopus.com/inward/record.url?scp=0023640869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023640869&partnerID=8YFLogxK

U2 - 10.1007/BF00252965

DO - 10.1007/BF00252965

M3 - Article

VL - 20

SP - 78

EP - 80

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -